New Indication for Tagrisso
April 18, 2018 – The U.S. FDA has approved a new indication for Tagrisso® (osimertinib), manufactured by AstraZeneca. The drug can now be used as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) in patients whose tumors are positive, according to an FDA-approved diagnostic test, for epidermal growth factor receptor (EGFR) mutations.
In clinical trials, Tagrisso was shown to extend the length of progression-free survival (18.9 months) compared to the current standard of care (10.2 months), which consists of tyrosine kinase inhibitors (TKIs). Risk of disease progression and death fell 54% with Tagrisso versus TKIs.
AstraZeneca expects the drug to reach a $3 billion sales goal following the new indication. First approved in 2015, Tagrisso is also indicated to treat metastatic EGFR mutation positive NSCLC in patients whose disease has progressed during or after TKI therapy.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.